blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3953351

EP3953351 - CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  09.11.2023
Database last updated on 28.09.2024
FormerRequest for examination was made
Status updated on  14.01.2022
FormerThe international publication has been made
Status updated on  16.10.2020
Formerunknown
Status updated on  11.05.2020
Most recent event   Tooltip13.04.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Opna Bio SA
Route de la Corniche 6
1066 Epalinges / CH
[2023/21]
Former [2022/24]For all designated states
Opna Immuno Oncology, SA
Route de la Corniche 6
1066 Epalinges / CH
Former [2022/07]For all designated states
Plexxikon Inc.
329 Oyster Point Boulevard
South San Francisco, CA 94080 / US
Inventor(s)01 / SPEVAK, Wayne
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
02 / BUELL, John
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
03 / GUO, Zuojun
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
04 / INAGAKI, Hiroaki
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
05 / JIN, Yongil
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
06 / PHAM, Phuongly
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
07 / SHI, Songyuan
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
08 / WALLESHAUSER, Jack
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
09 / WU, Jeffrey
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
10 / WU, Guoxian
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
11 / ZHANG, Chao
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
12 / ZHANG, Jiazhong
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
13 / ZHANG, Ying
c/o Plexxikon Inc.
329 Oyster Point Blvd South
San Francisco, CA 94080 / US
 [2022/07]
Representative(s)Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
[N/P]
Former [2022/07]Wallace, Sheila Jane
Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
Application number, filing date20722870.108.04.2020
[2022/07]
WO2020US27282
Priority number, dateUS201962831622P09.04.2019         Original published format: US 201962831622 P
[2022/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020210366
Date:15.10.2020
Language:EN
[2020/42]
Type: A1 Application with search report 
No.:EP3953351
Date:16.02.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 15.10.2020 takes the place of the publication of the European patent application.
[2022/07]
Search report(s)International search report - published on:EP15.10.2020
ClassificationIPC:C07D471/04, A61K31/437, A61P35/00
[2022/07]
CPC:
C07D471/04 (EP,IL,KR,US); A61K31/444 (IL,KR,US); A61K31/437 (IL,US);
A61K31/497 (IL,US); A61K31/501 (IL,US); A61K31/506 (IL,KR,US);
A61K45/06 (IL,KR,US); A61P25/28 (KR); A61P35/00 (EP,IL,KR);
C07D413/04 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/07]
Extension statesBA05.11.2021
ME05.11.2021
TitleGerman:KONDENSIERTE AZINE FÜR EP300- ODER CBP-MODULATION UND INDIKATIONEN DAFÜR[2022/07]
English:CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR[2022/07]
French:AZINES CONDENSÉES POUR LA MODULATION EP300 OU CBP ET INDICATIONS POUR CELLES-CI[2022/07]
Entry into regional phase05.11.2021National basic fee paid 
05.11.2021Designation fee(s) paid 
05.11.2021Examination fee paid 
Examination procedure05.11.2021Examination requested  [2022/07]
05.11.2021Date on which the examining division has become responsible
20.06.2022Amendment by applicant (claims and/or description)
08.11.2023Despatch of a communication from the examining division (Time limit: M04)
04.03.2024Reply to a communication from the examining division
Fees paidRenewal fee
27.04.2022Renewal fee patent year 03
12.04.2023Renewal fee patent year 04
12.04.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]WO2009054941  (MERCK & CO INC [US], et al) [X] 1-5,7-20,22 * step 1, intermediate: 1H-Pyrrolo[2,3-b]pyridine, 5-(1-methyl-1H-pyrazol-4-yl)-1- (phenylsulfonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-;; example 1 * [I] 6,21;
 [XI]WO2012129338  (AMGEN INC [US], et al) [X] 1-5,7-20,22 * examples 54b,54 * [I] 6,21;
 [XI]WO2013075785  (MERCK PATENT GMBH [DE]) [X] 1-5,7-20,22 * Intermediate; page 64 * * claim - * [I] 6,21;
 [XI]WO2014053568  (SANOFI SA [FR]) [X] 1-5,7-20,22 * stage 5, intermediate; page 119; example 14 * [I] 6,21;
 [I]WO2014145051  (ZHANG JIAZHONG [US], et al) [I] 1-37 * table - * * page 97 - page 261; example - * * claim - *;
 [I]WO2014154760  (BOEHRINGER INGELHEIM INT [DE]) [I] 1-37 * example - ** claim - *;
 [I]WO2017053243  (PLEXXIKON INC [US]) [I] 1-37 * page 49 - page 65; example - * * table - * * claim - *;
 [I]WO2018175311  (PLEXXIKON INC [US]) [I] 1-37 * the whole document * * example - * * claim - *;
 [IP]WO2019075243  (PLEXXIKON INC [US]) [IP] 1-37 * the whole document * * example - * * claim - *;
 [XI]  - ANU J. AIRAKSINEN ET AL, "Radiosynthesis and evaluation of new [alpha]1-adrenoceptor antagonists as PET radioligands for brain imaging", NUCLEAR MEDICINE AND BIOLOGY., US, (20130801), vol. 40, no. 6, doi:10.1016/j.nucmedbio.2013.05.007, ISSN 0969-8051, pages 747 - 754, XP055712575 [X] 1-5,7-20,22-24 * figure 1 * * Scheme 1 * [I] 6,21

DOI:   http://dx.doi.org/10.1016/j.nucmedbio.2013.05.007
 [XI]  - JØRGENSEN MORTEN ET AL, "Discovery of novel [alpha]1-adrenoceptor ligands based on the antipsychotic sertindole suitable for labeling as PET ligands", BIOORGANIC & MEDICINAL CHEMISTRY : A TETRAHEDRON PUBLICATION FOR THE RAPID DISSEMINATION OF FULL ORIGINAL RESEARCH PAPERS AND CRITICAL REVIEWS ON BIOMOLECULAR CHEMISTRY, MEDICINAL CHEMISTRY AND RELATED DISCIPLINES, (20121115), vol. 21, no. 1, doi:10.1016/J.BMC.2012.10.049, ISSN 0968-0896, pages 196 - 204, XP028961411 [X] 1-5,7-20,22-24 * table 1 * * Schemes 3,4 * [I] 6,21

DOI:   http://dx.doi.org/10.1016/j.bmc.2012.10.049
by applicantUS4150949
 EP0154734
 US4568649
 US4626513
 US2004077595
    - GIOTOPOULOS et al., "The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia", Oncogene, (20160121), vol. 35, no. 3, pages 279 - 289
    - PEREZ-SALVIA et al., Bromodomain inhibitors and cancer therapy: From structures to applications, Epigenetics & Chromatin, (20180000), vol. 11, page 30
    - MULLIGHAN et al., "CREBBP mutations in relapsed acute lymphoblastic leukemia", Nature, (20110000), vol. 471, no. 7337, pages 235 - 9
    - CONERY et al., Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma, URL: https://doi.org/10.7554/eLife.10483.001
    - MADEO et al., "Spermidine delays ageing in humans", Aging, (20180000), vol. 10, no. 8
    - GARCIA-CARPIZO et al., "CREBBP/EP300 bromodomain inhibitors in breast cancer", Mol. Cancer Res., (20190300), vol. 17, no. 3
    - BERGE, S. M. et al., "Pharmaceutical Salts", J. Pharmaceutical Science, (19770000), vol. 66, doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - UNDENFRIEND et al., Anal. Biochem., (19870000), vol. 161, pages 494 - 500
    - J Control Release, (20151210), vol. 219, pages 396 - 405
    - BERTOLINI et al., J. Med. Chem., (19970000), vol. 40, pages 2011 - 2016
    - SHAN et al., J Pharm Sci, (19970000), vol. 86, no. 7, pages 756 - 757
    - BAGSHAWE, Drug Dev. Res., (19950000), vol. 34, pages 220 - 230
    - JERRY MARCH, Advanced Organic Chemistry: Reactions, Mechanisms and Structures, John Wiley & Sons, (19920000), pages 69 - 74
    - VELY F. et al., "BIAcore® analysis to test phosphopeptide-SH2 domain interactions", Methods in Molecular Biology, (20000000), vol. 121, pages 313 - 21
    - LIPAROTO et al., "Biosensor analysis of the interleukin-2 receptor complex", Journal of Molecular Recognition, (19990000), vol. 12, doi:10.1002/(SICI)1099-1352(199909/10)12:5<316::AID-JMR468>3.3.CO;2-T, pages 316 - 21, XP001070799

DOI:   http://dx.doi.org/10.1002/(SICI)1099-1352(199909/10)12:5<316::AID-JMR468>3.3.CO;2-T
    - LIPSCHULTZ et al., "Experimental design for analysis of complex kinetics using surface plasmon resonance", Methods, (20000000), vol. 20, no. 3, doi:10.1006/meth.1999.0924, pages 310 - 8, XP004466887

DOI:   http://dx.doi.org/10.1006/meth.1999.0924
    - MALMQVIST., "BIACORE: an affinity biosensor system for characterization of biomolecular interactions", Biochemical Society Transactions, (19990000), vol. 27, pages 335 - 40, XP000956194
    - ALFTHAN, "Surface plasmon resonance biosensors as a tool in antibody engineering", Biosensors & Bioelectronics, (19980000), vol. 13, doi:10.1016/S0956-5663(98)00020-7, pages 653 - 63, XP026050117

DOI:   http://dx.doi.org/10.1016/S0956-5663(98)00020-7
    - FIVASH et al., "BIAcore for macromolecular interaction", Current Opinion in Biotechnology, (19980000), vol. 9, pages 97 - 101
    - PRICE et al., "Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC 1 mucin", Tumour Biology, (19980000), vol. 19, no. 1, pages 1 - 20
    - MALMQVIST et al., "Biomolecular interaction analysis: affinity biosensor technologies for functional analysis of proteins", Current Opinion in Chemical Biology, (19970000), vol. 1, doi:10.1016/S1367-5931(97)80077-4, pages 378 - 83, XP002978720

DOI:   http://dx.doi.org/10.1016/S1367-5931(97)80077-4
    - O'SHANNESSY et al., "Interpretation of deviations from pseudo-first-order kinetic behavior in the characterization of ligand binding by biosensor technology", Analytical Biochemistry, (19960000), vol. 236, pages 275 - 83
    - MALMBORG et al., "BIAcore as a tool in antibody engineering", Journal of Immunological Methods, (19950000), vol. 183, doi:10.1016/0022-1759(95)00018-6, pages 7 - 13, XP004021020

DOI:   http://dx.doi.org/10.1016/0022-1759(95)00018-6
    - VAN REGENMORTEL, "Use of biosensors to characterize recombinant proteins", Developments in Biological Standardization, (19940000), vol. 83, pages 143 - 51
    - O'SHANNESSY, "Determination of kinetic rate and equilibrium binding constants for macromolecular interactions: a critique of the surface plasmon resonance literature", Current Opinions in Biotechnology, (19940000), vol. 5, doi:10.1016/S0958-1669(05)80072-2, pages 65 - 71, XP022839327

DOI:   http://dx.doi.org/10.1016/S0958-1669(05)80072-2
    - GORDON, A. J.FORD, R. A., The Chemist's Companion: A Handbook Of Practical Data, Techniques, And References, John Wiley and Sons, (19720000), page 437
    - DANDLIKER, W. B. et al., Methods in Enzymology, (19810000), vol. 74, pages 155 - 194
    - OWICKI et al., "Application of Fluorescence Polarization Assays in High-Throughput Screening", Genetic Engineering News, (19970000), vol. 17, page 27
    - CHECOVICH, W. J. et al., Nature, (19950000), vol. 375, pages 254 - 256
    - PARKER et al., "Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays", J Biomol Screen, (20000000), vol. 5, doi:10.1177/108705710000500204, pages 77 - 88, XP001039835

DOI:   http://dx.doi.org/10.1177/108705710000500204
    - HEIM et al., Curr. Biol., (19960000), vol. 6, pages 178 - 182
    - MITRA et al., Gene, (19960000), vol. 173, pages 13 - 17
    - SELVIN et al., Meth. Enzymol., (19950000), vol. 246, pages 300 - 345
    - HANSELMAN et al., J. Lipid Res., (19970000), vol. 38, pages 2365 - 2373
    - KAHL et al., Anal. Biochem., (19960000), vol. 243, pages 282 - 283
    - NICHOLS et al., Anal. Biochem., (19980000), vol. 257, pages 112 - 119
    - FIESERFIESER, Reagents for Organic Synthesis, John Wiley, and Sons, (19910000), vol. 1-40
    - Larock's Comprehensive Organic Transformations, Elsevier Science Publishers, (19890000), vol. 1-5
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.